BMO Capital Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $14

Benzinga Newsdesk www.benzinga.com Positive 90.1%

Neg 0% Neu 0% Pos 90.1%

BMO Capital analyst Keith Tapper maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $10 to $14.